Earlier this year The New York Times highlighted an unexpected but serious risk for the American consumer when a doctor or chemist prescribes or dispenses generic equivalent drugs, rather than the original patented brand. Who does one sue?
This is potentially of concern to South Africans, as generic equivalent medicines are widely used here, where approval and licensing procedures closely follow American precedents. The issue is graphically demonstrated by two case studies quoted in The New York Times.
Like to see more ?
Subscribe to our on-line edition !
For a mere R298.00 per year you get the convenience of our online version including:- Twelve monthly issues of Noseweek delivered to your browser
- A searchable archive
- Access to every back issue since 1993 !
- A downloadable PDF version
If it's just this article you are after, you can purchase it for R30.00 by clicking here.
Tempted ?
For a taste of what awaits you, you are welcome to browse Last month's issue for free !









Previous Issues